Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.King Pharmaceuticals and Inyx have entered into a 10-year strategic co-marketing collaboration relating to King's asthma medicines Intal and Tilade.
Subscribe to our email newsletter
The collaboration will include the continued development of a new formulation of Intal utilizing hydrofluoroalkane (HFA), an environmentally friendly propellant.
King and Inyx will co-market Intal and Tilade and each have a share in net revenues. King will continue marketing to hospitals and primary care physicians, while Inyx will pursue direct sales to the specialist markets, including pediatricians, allergists and pulmonologists.
Inyx also plans to supervise the distribution of Intal HFA in Canada, following the receipt of necessary Canadian regulatory approval.
“Inyx’s focus on respiratory products and technical expertise with aerosol delivery provide King with a good strategic partner for enhancing the development and growth of our lead respiratory products, Intal and Tilade,” stated Brian Markison, president and CEO of King. “These capabilities should prove particularly valuable as we collaborate with Inyx to continue the development of an HFA formulation of Intal.”
The strategic alliance includes several 10-year agreements, with renewal options, and the formation of an alliance management committee comprised of three senior executives from each company.